Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 268.06M | 270.92M | 256.26M | 249.38M | 246.46M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 268.06M | 270.92M | 256.26M | 249.38M | 246.46M |
| Cost of Revenue | 147.34M | 143.57M | 132.59M | 128.75M | 132.51M |
| Gross Profit | 120.72M | 127.35M | 123.68M | 120.63M | 113.95M |
| SG&A Expenses | 73.52M | 72.50M | 68.33M | 66.79M | 64.63M |
| Depreciation & Amortization | 30.92M | 32.39M | 32.96M | 33.32M | 33.19M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 268.40M | 265.43M | 248.72M | 243.49M | 243.94M |
| Operating Income | -340.00K | 5.49M | 7.54M | 5.89M | 2.52M |
| Income Before Tax | 6.31M | 1.29M | -23.55M | -17.37M | -17.73M |
| Income Tax Expenses | -1.52M | -1.65M | -945.40K | -1.84M | -5.00M |
| Earnings from Continuing Operations | 7.83 | 2.94 | -22.61 | -15.52 | -12.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 7.83M | 2.94M | -22.61M | -15.52M | -12.73M |
| EBIT | -340.00K | 5.49M | 7.54M | 5.89M | 2.52M |
| EBITDA | 33.90M | 40.99M | 42.16M | 40.90M | 36.96M |
| EPS Basic | 0.08 | 0.03 | -0.22 | -0.15 | -0.13 |
| Normalized Basic EPS | 0.07 | 0.09 | 0.02 | 0.06 | 0.06 |
| EPS Diluted | 0.07 | 0.02 | -0.22 | -0.16 | -0.13 |
| Normalized Diluted EPS | 0.07 | 0.09 | 0.02 | 0.06 | 0.06 |
| Average Basic Shares Outstanding | 402.64M | 404.17M | 407.35M | 412.47M | 419.62M |
| Average Diluted Shares Outstanding | 403.48M | 404.58M | 407.35M | 412.73M | 420.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |